Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)
Professor Keith M. Kerr on fine points of testing for EGFR exon 20 insertion mutations in management of advanced NSCLC, commentary from Clinical Care Options (CCO)
David Planchard, MD, PhD, discusses barriers to osimertinib access worldwide and future directions for the management of advanced EGFR-mutated NSCLC.
On-demand webcast from a live CCO webinar capturing global perspectives from Drs. Edward S. Kim and Luis Paz-Ares on the optimal management of patients with EGFR+ NSCLC